Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Century Therapeutics Inc (IPSC)

Century Therapeutics Inc (IPSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Century Therapeutics to Participate in Upcoming Investor Conferences in March GlobeNewswire - Wed Feb 25, 7:00AM CST

PHILADELPHIA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies...

IPSC : 2.18 (+2.35%)
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes GlobeNewswire - Thu Jan 8, 7:00AM CST

PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies...

IPSC : 2.18 (+2.35%)
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors GlobeNewswire - Tue Dec 9, 2025

PHILADELPHIA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies...

IPSC : 2.18 (+2.35%)
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference GlobeNewswire - Tue Nov 25, 2025

PHILADELPHIA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies...

IPSC : 2.18 (+2.35%)
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire - Thu Nov 13, 2025

Announced iPSC derived beta islet cell program for Type 1 diabetes (T1D); Investigational New Drug (IND)-enabling studies expected to initiate by year-end 2025; IND submission planned in 2026 CNTY-308...

IPSC : 2.18 (+2.35%)
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes GlobeNewswire - Thu Nov 13, 2025

Allo-Evasion™ 5.0-engineered iPSC beta islets are designed to overcome immune rejection and provide durable glucose control without chronic immunosuppression Compelling preclinical data demonstrate...

IPSC : 2.18 (+2.35%)
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference GlobeNewswire - Tue Oct 14, 2025

PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies...

IPSC : 2.18 (+2.35%)
Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference GlobeNewswire - Fri Aug 22, 2025

PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell...

IPSC : 2.18 (+2.35%)
Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update GlobeNewswire - Thu Aug 14, 2025

Patient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated autoimmune diseases by year-end 2025 CNTY-308, a CAR-iT cell therapy functionally...

IPSC : 2.18 (+2.35%)
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress GlobeNewswire - Wed May 28, 2025

IPSC : 2.18 (+2.35%)

Barchart Exclusives

This Dividend Stock Has Been the Ultimate 'Trump Trade': Should You Buy? Barchart - 1 hour ago
AngloGold Ashanti shares have risen nearly fourfold over the last year. The company also has a healthy trailing dividend yield of 3%. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot